Physician profile
David I Andrews
NPI 1073860920
$12,194.47
in general payments reported to CMS, 2019-2025
14 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.11 · 2022: $903 · 2023: $93.93 · 2024: $10K · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,500 · Food and Beverage: $1,319 · Honoraria: $300 · Travel and Lodging: $88.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,500.00 |
| Food and Beverage | $1,318.75 |
| Honoraria | $300.00 |
| Travel and Lodging | $88.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $9,941.44 | 2024-2025 | Ycanth |
| Genzyme Corporation | $1,298.15 | 2022-2025 | |
| Chiesi USA, INC. | $328.45 | 2024-2025 | Filsuvez |
| Abbvie INC. | $237.34 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $83.28 | 2022-2025 | |
| Pfizer INC. | $61.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.62 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $46.70 | 2024-2025 | Nemluvio, Aklief |
| Organon LLC | $33.02 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $28.35 | 2025 | Dupixent |
| Botanix Sb INC | $24.12 | 2025 | Sofdra |
| Krystal Biotech INC | $21.14 | 2025 | Vyjuvek |
| Lilly USA, LLC | $20.20 | 2025 | Ebglyss |
| Leo Pharma INC. | $13.70 | 2024 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.